JP2014210782A - 結晶化を阻害する物質を含んでいる組成物 - Google Patents
結晶化を阻害する物質を含んでいる組成物 Download PDFInfo
- Publication number
- JP2014210782A JP2014210782A JP2014114845A JP2014114845A JP2014210782A JP 2014210782 A JP2014210782 A JP 2014210782A JP 2014114845 A JP2014114845 A JP 2014114845A JP 2014114845 A JP2014114845 A JP 2014114845A JP 2014210782 A JP2014210782 A JP 2014210782A
- Authority
- JP
- Japan
- Prior art keywords
- plasma
- dialysis
- composition
- inositol
- dialysate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 68
- 239000000126 substance Substances 0.000 title claims abstract description 53
- 238000002425 crystallisation Methods 0.000 title claims abstract description 23
- 230000008025 crystallization Effects 0.000 title claims abstract description 23
- 239000003112 inhibitor Substances 0.000 title description 7
- 238000000502 dialysis Methods 0.000 claims abstract description 61
- INAPMGSXUVUWAF-GCVPSNMTSA-N [(2r,3s,5r,6r)-2,3,4,5,6-pentahydroxycyclohexyl] dihydrogen phosphate Chemical compound OC1[C@H](O)[C@@H](O)C(OP(O)(O)=O)[C@H](O)[C@@H]1O INAPMGSXUVUWAF-GCVPSNMTSA-N 0.000 claims abstract description 26
- 229940122361 Bisphosphonate Drugs 0.000 claims abstract description 22
- 150000004663 bisphosphonates Chemical class 0.000 claims abstract description 22
- 208000037273 Pathologic Processes Diseases 0.000 claims abstract description 8
- 230000009054 pathological process Effects 0.000 claims abstract description 8
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical group OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 claims description 47
- 238000011282 treatment Methods 0.000 claims description 35
- -1 inositol phosphates Chemical class 0.000 claims description 20
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Phytic acid Natural products OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 claims description 18
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 claims description 17
- 229910019142 PO4 Inorganic materials 0.000 claims description 17
- 229960000367 inositol Drugs 0.000 claims description 17
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims description 17
- 235000021317 phosphate Nutrition 0.000 claims description 16
- 238000001990 intravenous administration Methods 0.000 claims description 15
- 150000003839 salts Chemical class 0.000 claims description 15
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims description 7
- 230000002265 prevention Effects 0.000 claims description 7
- 229940068041 phytic acid Drugs 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 2
- 230000001575 pathological effect Effects 0.000 abstract description 5
- 230000035790 physiological processes and functions Effects 0.000 abstract description 3
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 235000002949 phytic acid Nutrition 0.000 description 42
- DBVJJBKOTRCVKF-UHFFFAOYSA-N Etidronic acid Chemical compound OP(=O)(O)C(O)(C)P(O)(O)=O DBVJJBKOTRCVKF-UHFFFAOYSA-N 0.000 description 33
- 229940009626 etidronate Drugs 0.000 description 31
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 24
- 239000007788 liquid Substances 0.000 description 23
- 230000036470 plasma concentration Effects 0.000 description 19
- 238000009472 formulation Methods 0.000 description 18
- 239000012528 membrane Substances 0.000 description 14
- 210000004379 membrane Anatomy 0.000 description 13
- 239000008280 blood Substances 0.000 description 12
- 210000004369 blood Anatomy 0.000 description 12
- 239000011780 sodium chloride Substances 0.000 description 12
- 238000000034 method Methods 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 238000001631 haemodialysis Methods 0.000 description 9
- 230000000322 hemodialysis Effects 0.000 description 9
- 239000000385 dialysis solution Substances 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 239000007853 buffer solution Substances 0.000 description 7
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 7
- 208000004434 Calcinosis Diseases 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- 230000002308 calcification Effects 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 235000011180 diphosphates Nutrition 0.000 description 6
- 230000008034 disappearance Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 5
- 239000011575 calcium Substances 0.000 description 5
- 229910052791 calcium Inorganic materials 0.000 description 5
- 239000001913 cellulose Substances 0.000 description 5
- 229920002678 cellulose Polymers 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- 239000003792 electrolyte Substances 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 239000002699 waste material Substances 0.000 description 4
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 208000001647 Renal Insufficiency Diseases 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000009792 diffusion process Methods 0.000 description 3
- 230000002526 effect on cardiovascular system Effects 0.000 description 3
- 230000029142 excretion Effects 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 201000006370 kidney failure Diseases 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- 229910052749 magnesium Inorganic materials 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000011591 potassium Substances 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- MPBVHIBUJCELCL-UHFFFAOYSA-N Ibandronate Chemical compound CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O MPBVHIBUJCELCL-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 206010029148 Nephrolithiasis Diseases 0.000 description 2
- IIDJRNMFWXDHID-UHFFFAOYSA-N Risedronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CC1=CC=CN=C1 IIDJRNMFWXDHID-UHFFFAOYSA-N 0.000 description 2
- DKJJVAGXPKPDRL-UHFFFAOYSA-N Tiludronic acid Chemical compound OP(O)(=O)C(P(O)(O)=O)SC1=CC=C(Cl)C=C1 DKJJVAGXPKPDRL-UHFFFAOYSA-N 0.000 description 2
- 229960004343 alendronic acid Drugs 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 229960002286 clodronic acid Drugs 0.000 description 2
- ACSIXWWBWUQEHA-UHFFFAOYSA-N clodronic acid Chemical compound OP(O)(=O)C(Cl)(Cl)P(O)(O)=O ACSIXWWBWUQEHA-UHFFFAOYSA-N 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 229960004585 etidronic acid Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 229960001031 glucose Drugs 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 229960005236 ibandronic acid Drugs 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229940001447 lactate Drugs 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- WRUUGTRCQOWXEG-UHFFFAOYSA-N pamidronate Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 description 2
- 229960003978 pamidronic acid Drugs 0.000 description 2
- 239000004926 polymethyl methacrylate Substances 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000008085 renal dysfunction Effects 0.000 description 2
- 229960000759 risedronic acid Drugs 0.000 description 2
- 229920002994 synthetic fiber Polymers 0.000 description 2
- 229960005324 tiludronic acid Drugs 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 229960004276 zoledronic acid Drugs 0.000 description 2
- XRASPMIURGNCCH-UHFFFAOYSA-N zoledronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 208000006386 Bone Resorption Diseases 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 208000000913 Kidney Calculi Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- 229920005372 Plexiglas® Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- MZVQCMJNVPIDEA-UHFFFAOYSA-N [CH2]CN(CC)CC Chemical group [CH2]CN(CC)CC MZVQCMJNVPIDEA-UHFFFAOYSA-N 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- 208000022458 calcium metabolism disease Diseases 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000003831 deregulation Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 230000006911 nucleation Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000467 phytic acid Substances 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920002492 poly(sulfone) Polymers 0.000 description 1
- 229920002239 polyacrylonitrile Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
- A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/727—Heparin; Heparan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/42—Phosphorus; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0026—Blood substitute; Oxygen transporting formulations; Plasma extender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
- A61M1/16—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes
- A61M1/1654—Dialysates therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
- A61M1/28—Peritoneal dialysis ; Other peritoneal treatment, e.g. oxygenation
- A61M1/287—Dialysates therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Inorganic Chemistry (AREA)
- Vascular Medicine (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- External Artificial Organs (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
該結晶化を阻害する物質は、イノシトールリン酸、ビスホスホネートもしくは薬学的に受容可能なそれらの塩、またはそれらの組合せのいずれか、を含んでいる群から選択される、組成物。
〔2〕前記結晶化を阻害する物質は、1〜6個のリン酸基を含んでいるイノシトールリン酸である、1に記載の組成物。
〔3〕前記イノシトールリン酸はイノシトール六リン酸である、2に記載の組成物。
〔4〕前記イノシトールリン酸はミオイノシトール六リン酸である、3に記載の組成物。
〔5〕上記ビスホスホネートは、エチドロン酸、アレンドロン酸、リセドロン酸、ゾレドロン酸、チルドロン酸、パミドロン酸、クロドロン酸、イバンドロン酸もしくはそれらの塩、またはそれらの組合せのいずれか、を含んでいる群から選択される、1に記載の組成物。
〔6〕ピロリン酸をさらに含んでいる、1〜5の何れか1項に記載の組成物。
〔7〕イノシトールリン酸、ビスホスホネートもしくは薬学的に受容可能なそれらの塩、またはそれらの組合せのいずれか、を含んでいる群から選択される結晶化を阻害する物質を含んでいる、透析液。
〔8〕血液透析または腹膜透析に使用するための、7に記載の透析液。
〔9〕イノシトールリン酸および/またはその塩のいずれかを含んでいる、静脈内投与に適した形態の組成物であって、
血漿中の該物質が生理学的に適切なレベルに調節されていないことに関連する病理的なプロセスの治療または予防に用いられる、組成物。
〔10〕前記イノシトールリン酸は1〜6個のリン酸基を含んでいる、9に記載の組成物。
〔11〕前記イノシトールリン酸はイノシトール六リン酸である、10に記載の組成物。
〔12〕前記イノシトールリン酸はミオイノシトール六リン酸である、11に記載の組成物。
〔13〕ピロリン酸をさらに含んでいる、9〜12の何れか1項に記載の組成物。
〔14〕前記調節されていないことの治療または予防は、透析を受ける個体の血漿中の前記物質のレベルを維持するか、または上昇させることによって行われる、9〜13の何れか1項に記載の組成物。
〔15〕イノシトールリン酸、ビスホスホネートもしくは薬学的に許容できるそれらの塩、またはそれらの組合せのいずれか、を含んでいる群から選択される結晶化を阻害する物質を含んでいる組成物と、
透析を受ける患者の血漿中の該物質が生理学的に適切なレベルに調節されないことに関連する病理的なプロセスの治療または予防に、別々に、同時にまたは連続して用いられる透析液と、
を少なくとも含んでいる混合調製物。
〔16〕静脈内投与に適した形態である、15に記載の混合調製物。
生理的なおよび/または病的な結晶化および石灰化のプロセスを調節するために貢献し得る特定の物質の生理的濃度を効果的に維持する必要がある。
図1は、フィテートを含んでいない透析液を用いた透析処理の間に、クリアランスによって人工血漿サンプル中のフィテートの40%までが、20時間の間に失われることを示す図である。
以下に、本発明者によって行われた分析に基づいて本発明を説明し、注射または点滴静注または透析液の形態にて投与される本発明の組成物の特性および有効性を示す。
人工血漿(血漿の組成に類似する組成を有する液体)を1.5mMのフィテートで調製し、イオン強度を0.15MのNaClで調節した。この液体25mLをフィテートを含んでいない0.15MのNaCl溶液1L(透析用の液体のモデル)に対して20時間透析した。両方の液体のpHを重炭酸塩の緩衝液を用いて7.4に調節した。
人工血漿を1.5mMフィテートで調製し、イオン強度を0.15MのNaClで調節した。この液体25mLを上記血漿と同じフィテート濃度を有する0.15MのNaCl溶液1Lに対して20時間透析した。両方の液体のpHを重炭酸塩の緩衝液を用いて7.4に調節した。
人工血漿を300μMフィテートで調製し、イオン強度を0.15MのNaClで調節した。この液体25mLを上記血漿の5倍のフィテートの濃度を有する0.15MのNaCl溶液1Lに対して20時間透析した。両方の液体のpHを重炭酸塩の緩衝液を用いて7.4に調節した。
人工血漿を5mMエチドロネートで調製し、イオン強度を0.15MのNaClで調節した。この液体25mLをエチドロネートを含まない0.15MのNaCl溶液1L(透析用の液体のモデル)に対して20時間透析した。両方の液体のpHを重炭酸塩の緩衝液を用いて7.4に調節した。
人工血漿を5mMエチドロネートで調製し、イオン強度を0.15MのNaClで調節した。この液体25mLを上記血漿と同じエチドロネート濃度を有する0.15MのNaCl溶液1Lに対して20時間透析した。両方の液体のpHを重炭酸塩緩衝液を用いて7.4に調節した。
人工血漿を1mMエチドロネートで調製し、イオン強度を0.15MのNaClで調節した。この液体25mLを上記血漿の5倍のエチドロネート濃度を有する0.15MのNaCl溶液1Lに対して20時間透析した。両方の液体のpHを重炭酸塩の緩衝液を用いて7.4に調節した。
イノシトールリン酸および/またはビスホスホネートを添加した(血液透析および腹膜透析の両方のための)透析液の組成物。
フィテートを含んでいるイノシトールリン酸を添加した、種々の医療措置(注射または静脈内注射および血液透析または腹膜透析による治療の両方)を受ける患者の静脈内に投与するための処方物の組成物。イノシトールリン酸の濃度は、表に示す量を得るために、静脈内投与の量の関数として調整される。
重量約250gの6匹の雄のウィスターラットを、12:12の明暗サイクルでケージ(T=1±1℃、湿度=60±5%)において7日間(fro 7 dias)順応させた。ラットはプレキシグラスのケージに一匹ずつ入れ、餌と飲み物とを自由に与えた。
Claims (6)
- イノシトールリン酸および/またはその塩のいずれかを含んでいる組成物の使用であって、
血漿中のイノシトールリン酸および/またはその塩が生理学的に適切なレベルに調節されていないことに関連する病理的なプロセスの治療または予防に用いられる、静脈内投与に適した形態の薬剤の製造のための、使用。 - 前記イノシトールリン酸は1〜6個のリン酸基を含んでいる、請求項1に記載の使用。
- 前記イノシトールリン酸はイノシトール六リン酸である、請求項2に記載の使用。
- 前記イノシトールリン酸はミオイノシトール六リン酸である、請求項3に記載の使用。
- 透析を受ける患者の血漿中の結晶化を阻害する物質が生理学的に適切なレベルに調節されないことに関連する病理的なプロセスの治療または予防のための薬剤を製造するための混合調製物の使用であって、
前記混合調製物は、イノシトールリン酸、ビスホスホネートもしくは薬学的に許容できるそれらの塩、またはそれらの組合せのいずれか、を含んでいる群から選択される結晶化を阻害する物質を含んでいる組成物と、透析液とを少なくとも含み、
前記組成物と前記透析液とが、別々に、同時に、または連続して混合される、使用。 - 前記薬剤は静脈内投与に適した形態である、請求項5に記載の使用。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES200802363A ES2332636B1 (es) | 2008-08-06 | 2008-08-06 | Composicion de liquido de dialisis. |
ESP200802363 | 2008-08-06 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011521603A Division JP2011529759A (ja) | 2008-08-06 | 2009-05-14 | 結晶化を阻害する物質を含んでいる組成物 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016145416A Division JP6412068B2 (ja) | 2008-08-06 | 2016-07-25 | 薬剤を製造するための、イノシトールリン酸および/またはその塩のいずれかを含んでいる組成物の使用 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2014210782A true JP2014210782A (ja) | 2014-11-13 |
JP5978251B2 JP5978251B2 (ja) | 2016-08-24 |
Family
ID=41058532
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011521603A Pending JP2011529759A (ja) | 2008-08-06 | 2009-05-14 | 結晶化を阻害する物質を含んでいる組成物 |
JP2014114845A Active JP5978251B2 (ja) | 2008-08-06 | 2014-06-03 | 結晶化を阻害する物質を含んでいる組成物 |
JP2016145416A Active JP6412068B2 (ja) | 2008-08-06 | 2016-07-25 | 薬剤を製造するための、イノシトールリン酸および/またはその塩のいずれかを含んでいる組成物の使用 |
JP2018189323A Active JP6799041B2 (ja) | 2008-08-06 | 2018-10-04 | 薬剤を製造するための、イノシトールリン酸および/またはその塩のいずれかを含んでいる組成物の使用 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011521603A Pending JP2011529759A (ja) | 2008-08-06 | 2009-05-14 | 結晶化を阻害する物質を含んでいる組成物 |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016145416A Active JP6412068B2 (ja) | 2008-08-06 | 2016-07-25 | 薬剤を製造するための、イノシトールリン酸および/またはその塩のいずれかを含んでいる組成物の使用 |
JP2018189323A Active JP6799041B2 (ja) | 2008-08-06 | 2018-10-04 | 薬剤を製造するための、イノシトールリン酸および/またはその塩のいずれかを含んでいる組成物の使用 |
Country Status (20)
Country | Link |
---|---|
US (4) | US8778912B2 (ja) |
EP (2) | EP3103456B1 (ja) |
JP (4) | JP2011529759A (ja) |
CN (2) | CN104224809A (ja) |
AU (1) | AU2009281096B2 (ja) |
BR (1) | BRPI0911938A2 (ja) |
CA (2) | CA2975801C (ja) |
CY (2) | CY1118089T1 (ja) |
DK (2) | DK2324835T3 (ja) |
ES (3) | ES2332636B1 (ja) |
HK (1) | HK1203843A1 (ja) |
HR (2) | HRP20161170T1 (ja) |
HU (2) | HUE031173T2 (ja) |
LT (2) | LT2324835T (ja) |
MX (1) | MX2011001278A (ja) |
PL (2) | PL3103456T3 (ja) |
PT (2) | PT3103456T (ja) |
RU (2) | RU2535094C2 (ja) |
SI (2) | SI2324835T1 (ja) |
WO (1) | WO2010018278A2 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2018516929A (ja) * | 2015-06-04 | 2018-06-28 | アモーフィカル リミテッド. | 吸入、舌下又は頬側投与のための非晶質炭酸カルシウムの組成物 |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2332636B1 (es) * | 2008-08-06 | 2011-02-10 | Universitat De Les Illes Balears | Composicion de liquido de dialisis. |
US9364490B2 (en) * | 2013-03-15 | 2016-06-14 | Laboratoris Sanifit, S.L. | Use of derivatives containing C—O—P bonds in patients with kidney failure |
ES2495666B1 (es) * | 2013-03-15 | 2015-08-10 | Laboratoris Sanifit, S.L. | Uso de derivados con enlaces c-o-p en pacientes con fallo renal |
DE102014013885A1 (de) | 2014-09-18 | 2016-03-24 | Fresenius Medical Care Deutschland Gmbh | Dialyselösung |
DE102015007842A1 (de) * | 2015-06-18 | 2016-12-22 | Fresenius Medical Care Deutschland Gmbh | Dialyselösung |
CN113788855B (zh) * | 2015-12-11 | 2024-03-01 | 苏黎世联邦理工学院 | 用于病理性结晶的肌醇衍生物 |
US11028112B2 (en) | 2015-12-11 | 2021-06-08 | Eth Zurich | Inositol derivatives for use in pathological crystallization |
US11707470B2 (en) | 2015-12-11 | 2023-07-25 | Eth Zurich | Inositol derivatives for use in pathological crystallization |
CN107550992B (zh) * | 2017-08-16 | 2018-05-25 | 安徽天康(集团)股份有限公司 | 一种治疗痛风的药物及其制备方法 |
BR112021006004A2 (pt) | 2018-10-11 | 2021-06-29 | Sanifit Therapeutics S.A. | inositol fosfatos para o tratamento de calcificações ectópicas. |
CN113365636A (zh) | 2019-01-30 | 2021-09-07 | 萨尼菲特治疗有限公司 | 用于增加组织灌注的磷酸肌醇化合物 |
EP3965775A4 (en) * | 2019-05-10 | 2023-05-10 | Fresenius Medical Care Deutschland GmbH | COMPOSITION AND CONCENTRATE FOR USE IN THE PREPARATION OF A DIALYSIS SOLUTION, CORRESPONDING DIALYSIS SOLUTION AND COMBINATIONS COMPRISING A CONTAINER |
EP3818983A1 (en) | 2019-11-11 | 2021-05-12 | Sanifit Therapeutics S.A. | Inositol phosphate compounds for use in treating, inhibiting the progression, or preventing cardiovascular calcification |
US11633416B1 (en) | 2020-03-06 | 2023-04-25 | Arcus Biosciences, Inc. | Oral formulations of CD73 compounds |
EP4015494A1 (en) | 2020-12-15 | 2022-06-22 | Sanifit Therapeutics S.A. | Processes for the preparation of soluble salts of inositol phosphates |
EP4036097A1 (en) | 2021-01-29 | 2022-08-03 | Sanifit Therapeutics S.A. | Ip4-4,6 substituted derivative compounds |
WO2024023360A1 (en) | 2022-07-29 | 2024-02-01 | Sanifit Therapeutics, S.A. | Ip5 substituted compounds |
WO2024023359A1 (en) | 2022-07-29 | 2024-02-01 | Sanifit Therapeutics, S.A. | Ip4-4,6 substituted derivative compounds for use in the treatment, inhibition of progression, and prevention of ectopic calcification |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH1149671A (ja) * | 1997-08-06 | 1999-02-23 | Baxter Internatl Inc | 腹膜透析液 |
JP2002249433A (ja) * | 2000-12-19 | 2002-09-06 | Sumitomo Pharmaceut Co Ltd | 血管石灰化抑制剤 |
JP2007510710A (ja) * | 2003-11-07 | 2007-04-26 | ラボラトリオス、サニフィト、ソシエダッド、リミターダ | 局所用のミオイノシトール6リン酸 |
JP2007523056A (ja) * | 2003-10-28 | 2007-08-16 | エモリー ユニバーシティ | 透析液並びに透析液に関連した方法及びシステム |
WO2007120484A2 (en) * | 2006-03-31 | 2007-10-25 | Oxyplus, Inc. | Use of inositol-tripyrophosphate in treating tumors and diseases |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2529463B1 (fr) * | 1982-07-05 | 1986-01-10 | Centre Nat Rech Scient | Procede et dispositif pour l'encapsulation dans les erythrocytes d'au moins une substance a activite biologique, notamment des effecteurs allosteriques de l'hemoglobine et erythrocytes ainsi obtenus |
US5330979A (en) * | 1984-10-23 | 1994-07-19 | Perstorp Ab | Method of treating renal disorders with inositoltriphosphate |
SE469260B (sv) * | 1992-02-25 | 1993-06-14 | Perstorp Ab | En farmaceutisk komposition med foerbaettrad biotillgaenglighet avseende inositolfosfat |
JP4143118B2 (ja) * | 1993-02-23 | 2008-09-03 | ブリガム・アンド・ウイミンズ・ホスピタル・インコーポレイテッド | カルシウム受容体活性化分子およびその関連物 |
RU2126973C1 (ru) * | 1997-10-07 | 1999-02-27 | Слюсарь Николай Николаевич | Способ коррекции нарушений фосфоинозитидного обмена |
EG24303A (en) * | 1998-10-20 | 2009-01-12 | Advanced Renal Technologies | Buffered compositions for dialysis |
DE19912850B4 (de) * | 1999-03-22 | 2005-04-07 | Fresenius Medical Care Deutschland Gmbh | Lösung, insbesondere für Hämo- oder Peritonealdialyse, sowie Verfahren zu deren Herstellung |
DE29910454U1 (de) * | 1999-06-10 | 1999-09-23 | Vitasyn Gmbh | Mittel zur Therapie von Hyperphosphatämie |
EP1223985B1 (en) * | 1999-10-15 | 2005-11-30 | Dow Global Technologies Inc. | Dialysis solution including polyglycol osmotic agent |
JP2003238414A (ja) * | 2001-12-13 | 2003-08-27 | Sangaku Renkei Kiko Kyushu:Kk | 医薬組成物 |
GB0328040D0 (en) * | 2003-12-03 | 2004-01-07 | Coleman Robert E | Pharmaceutical uses of bisphosphonates |
ES2288126B2 (es) * | 2006-06-01 | 2009-07-06 | Universitat De Les Illes Balears | Utilizacion de fitato como agente inhibidor de la disolucion de cristales de sales calcicas para la prevencion o tratamiento de la osteoporosis. |
ES2332636B1 (es) * | 2008-08-06 | 2011-02-10 | Universitat De Les Illes Balears | Composicion de liquido de dialisis. |
-
2008
- 2008-08-06 ES ES200802363A patent/ES2332636B1/es active Active
-
2009
- 2009-05-14 BR BRPI0911938A patent/BRPI0911938A2/pt not_active Application Discontinuation
- 2009-05-14 US US13/057,167 patent/US8778912B2/en active Active - Reinstated
- 2009-05-14 PL PL16172654T patent/PL3103456T3/pl unknown
- 2009-05-14 PT PT161726542T patent/PT3103456T/pt unknown
- 2009-05-14 MX MX2011001278A patent/MX2011001278A/es active IP Right Grant
- 2009-05-14 LT LTEP09784119.1T patent/LT2324835T/lt unknown
- 2009-05-14 JP JP2011521603A patent/JP2011529759A/ja active Pending
- 2009-05-14 LT LTEP16172654.2T patent/LT3103456T/lt unknown
- 2009-05-14 ES ES16172654T patent/ES2785566T3/es active Active
- 2009-05-14 SI SI200931518A patent/SI2324835T1/sl unknown
- 2009-05-14 CA CA2975801A patent/CA2975801C/en active Active
- 2009-05-14 CN CN201410359194.4A patent/CN104224809A/zh active Pending
- 2009-05-14 HU HUE09784119A patent/HUE031173T2/en unknown
- 2009-05-14 SI SI200932058T patent/SI3103456T1/sl unknown
- 2009-05-14 WO PCT/ES2009/070156 patent/WO2010018278A2/es active Application Filing
- 2009-05-14 HU HUE16172654A patent/HUE049269T2/hu unknown
- 2009-05-14 PT PT97841191T patent/PT2324835T/pt unknown
- 2009-05-14 PL PL09784119T patent/PL2324835T3/pl unknown
- 2009-05-14 EP EP16172654.2A patent/EP3103456B1/en active Active
- 2009-05-14 AU AU2009281096A patent/AU2009281096B2/en active Active
- 2009-05-14 DK DK09784119.1T patent/DK2324835T3/en active
- 2009-05-14 CA CA2732881A patent/CA2732881C/en active Active
- 2009-05-14 ES ES09784119.1T patent/ES2595227T3/es active Active
- 2009-05-14 EP EP09784119.1A patent/EP2324835B1/en active Active
- 2009-05-14 CN CN2009801357846A patent/CN102143754A/zh active Pending
- 2009-05-14 DK DK16172654.2T patent/DK3103456T3/da active
- 2009-05-14 RU RU2011115356/15A patent/RU2535094C2/ru active
-
2014
- 2014-02-12 US US14/178,893 patent/US9155750B2/en active Active
- 2014-06-03 JP JP2014114845A patent/JP5978251B2/ja active Active
- 2014-07-08 RU RU2014127746A patent/RU2691060C2/ru active
-
2015
- 2015-05-15 HK HK15104642.7A patent/HK1203843A1/xx unknown
- 2015-09-11 US US14/851,924 patent/US20150374752A1/en not_active Abandoned
-
2016
- 2016-07-25 JP JP2016145416A patent/JP6412068B2/ja active Active
- 2016-09-13 HR HRP20161170TT patent/HRP20161170T1/hr unknown
- 2016-09-30 CY CY20161100972T patent/CY1118089T1/el unknown
-
2017
- 2017-01-18 US US15/409,166 patent/US20170119799A1/en not_active Abandoned
-
2018
- 2018-10-04 JP JP2018189323A patent/JP6799041B2/ja active Active
-
2020
- 2020-04-29 CY CY20201100395T patent/CY1122973T1/el unknown
- 2020-05-07 HR HRP20200733TT patent/HRP20200733T1/hr unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH1149671A (ja) * | 1997-08-06 | 1999-02-23 | Baxter Internatl Inc | 腹膜透析液 |
JP2002249433A (ja) * | 2000-12-19 | 2002-09-06 | Sumitomo Pharmaceut Co Ltd | 血管石灰化抑制剤 |
JP2007523056A (ja) * | 2003-10-28 | 2007-08-16 | エモリー ユニバーシティ | 透析液並びに透析液に関連した方法及びシステム |
JP2007510710A (ja) * | 2003-11-07 | 2007-04-26 | ラボラトリオス、サニフィト、ソシエダッド、リミターダ | 局所用のミオイノシトール6リン酸 |
WO2007120484A2 (en) * | 2006-03-31 | 2007-10-25 | Oxyplus, Inc. | Use of inositol-tripyrophosphate in treating tumors and diseases |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2018516929A (ja) * | 2015-06-04 | 2018-06-28 | アモーフィカル リミテッド. | 吸入、舌下又は頬側投与のための非晶質炭酸カルシウムの組成物 |
JP7039006B2 (ja) | 2015-06-04 | 2022-03-22 | アモーフィカル リミテッド. | 吸入、舌下又は頬側投与のための非晶質炭酸カルシウムの組成物 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6412068B2 (ja) | 薬剤を製造するための、イノシトールリン酸および/またはその塩のいずれかを含んでいる組成物の使用 | |
JP6104155B2 (ja) | 腹膜透析治療の間に脈管石灰化を低下させるかまたは予防するための方法および組成物 | |
EP0958832A2 (en) | Albumin containing peritoneal dialysis fluid | |
CN1620308A (zh) | 含有表皮生长因子的药物组合物在预防糖尿病肢端坏疽截肢中的用途 | |
CN1481247A (zh) | 唑来膦酸盐在生产用于治疗骨代谢疾病的药物中的用途 | |
MXPA04012299A (es) | Una solucion estable a base de bicarbonato en un recipiente individual. | |
JP2021006262A (ja) | 透析装置、アクセプター薬剤、ドナー薬剤、リンス液およびリンス液としての使用方法 | |
JP2019516428A (ja) | 透析濃縮液 | |
RU2683939C1 (ru) | Способ внутривенной инфузии гипохлорита натрия, активации гликолиза, лечения доброкачественных и злокачественных новообразований, повышения эффективности химиотерапии злокачественных новообразований, лечения вторичной иммунной недостаточности при генерализованной бактериальной и вирусной инфекции | |
BG109160A (bg) | Средство с антитуморна активност на база бцж ваксина, метод за неговото получаване и използването му | |
CA3183133A1 (en) | Peritoneal dialysis solution |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150602 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20150828 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20151002 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160329 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160530 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20160628 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20160725 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5978251 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |